Annual Operating Expenses:
$304.43M+$5.11M(+1.71%)Summary
- As of today, HALO annual total operating expenses is $304.43 million, with the most recent change of +$5.11 million (+1.71%) on December 31, 2024.
- During the last 3 years, HALO annual operating expenses has risen by +$218.44 million (+254.01%).
- HALO annual operating expenses is now at all-time high.
Performance
HALO Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Operating Expenses:
$63.34M+$4.18M(+7.07%)Summary
- As of today, HALO quarterly total operating expenses is $63.34 million, with the most recent change of +$4.18 million (+7.07%) on September 30, 2025.
- Over the past year, HALO quarterly operating expenses has increased by +$3.64 million (+6.10%).
- HALO quarterly operating expenses is now at all-time high.
Performance
HALO Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
HALO Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +1.7% | +6.1% |
| 3Y3 Years | +254.0% | +24.8% |
| 5Y5 Years | +39.6% | +225.7% |
HALO Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +254.0% | at high | +24.8% |
| 5Y | 5-Year | at high | +280.7% | at high | +255.7% |
| All-Time | All-Time | at high | >+9999.0% | at high | >+9999.0% |
HALO Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $63.34M(+7.1%) |
| Jun 2025 | - | $59.16M(+3.5%) |
| Mar 2025 | - | $57.16M(-8.8%) |
| Dec 2024 | $304.43M(+1.7%) | $62.69M(+5.0%) |
| Sep 2024 | - | $59.70M(+5.2%) |
| Jun 2024 | - | $56.75M(+4.6%) |
| Mar 2024 | - | $54.24M(-8.0%) |
| Dec 2023 | $299.32M(+18.2%) | $58.94M(+12.1%) |
| Sep 2023 | - | $52.59M(-10.4%) |
| Jun 2023 | - | $58.67M(+6.0%) |
| Mar 2023 | - | $55.34M(-6.1%) |
| Dec 2022 | $253.28M(+194.5%) | $58.91M(+16.0%) |
| Sep 2022 | - | $50.77M(-6.6%) |
| Jun 2022 | - | $54.36M(+111.6%) |
| Mar 2022 | - | $25.69M(+7.6%) |
| Dec 2021 | $86.00M(+7.5%) | $23.88M(+10.3%) |
| Sep 2021 | - | $21.66M(+6.2%) |
| Jun 2021 | - | $20.39M(+1.6%) |
| Mar 2021 | - | $20.07M(+12.7%) |
| Dec 2020 | $79.97M(-63.3%) | $17.81M(-8.4%) |
| Sep 2020 | - | $19.45M(-2.4%) |
| Jun 2020 | - | $19.93M(-12.6%) |
| Mar 2020 | - | $22.79M(-40.2%) |
| Dec 2019 | $218.06M(+3.3%) | $38.08M(-21.4%) |
| Sep 2019 | - | $48.43M(-3.6%) |
| Jun 2019 | - | $50.25M(+1.9%) |
| Mar 2019 | - | $49.33M(-9.8%) |
| Dec 2018 | $211.06M(+3.2%) | $54.68M(+8.5%) |
| Sep 2018 | - | $50.40M(-7.4%) |
| Jun 2018 | - | $54.44M(+5.6%) |
| Mar 2018 | - | $51.53M(-8.2%) |
| Dec 2017 | $204.46M(+3.9%) | $56.15M(+18.6%) |
| Sep 2017 | - | $47.32M(-8.0%) |
| Jun 2017 | - | $51.44M(+3.8%) |
| Mar 2017 | - | $49.55M(-7.5%) |
| Dec 2016 | $196.69M(+47.6%) | $53.58M(+17.8%) |
| Sep 2016 | - | $45.46M(-2.8%) |
| Jun 2016 | - | $46.75M(-8.2%) |
| Mar 2016 | - | $50.91M(+32.8%) |
| Dec 2015 | $133.26M(+15.2%) | $38.34M(+1.3%) |
| Sep 2015 | - | $37.84M(+22.0%) |
| Jun 2015 | - | $31.01M(+18.9%) |
| Mar 2015 | - | $26.08M(-7.1%) |
| Dec 2014 | $115.64M(-10.3%) | $28.08M(-1.4%) |
| Sep 2014 | - | $28.49M(+4.0%) |
| Jun 2014 | - | $27.40M(-13.5%) |
| Mar 2014 | - | $31.66M(+4.6%) |
| Dec 2013 | $128.99M | $30.28M(-10.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $33.82M(-4.2%) |
| Jun 2013 | - | $35.29M(+19.3%) |
| Mar 2013 | - | $29.59M(+17.1%) |
| Dec 2012 | $94.86M(+25.4%) | $25.26M(+1.7%) |
| Sep 2012 | - | $24.85M(+16.2%) |
| Jun 2012 | - | $21.39M(-4.0%) |
| Mar 2012 | - | $22.27M(+296.1%) |
| Dec 2011 | $75.67M(+13.1%) | $5.62M(-67.9%) |
| Sep 2011 | - | $17.54M(-10.6%) |
| Jun 2011 | - | $19.63M(+16.4%) |
| Mar 2011 | - | $16.87M(-6.8%) |
| Dec 2010 | $66.90M(-6.9%) | $18.10M(+17.1%) |
| Sep 2010 | - | $15.46M(+3.8%) |
| Jun 2010 | - | $14.89M(+0.5%) |
| Mar 2010 | - | $14.81M(-20.2%) |
| Dec 2009 | $71.82M(+22.0%) | $18.57M(+12.5%) |
| Sep 2009 | - | $16.50M(-8.9%) |
| Jun 2009 | - | $18.11M(+5.3%) |
| Mar 2009 | - | $17.20M(-12.6%) |
| Dec 2008 | $58.87M(+85.6%) | $19.67M(+48.5%) |
| Sep 2008 | - | $13.25M(+5.8%) |
| Jun 2008 | - | $12.52M(+1.2%) |
| Mar 2008 | - | $12.37M(+12.3%) |
| Dec 2007 | $31.71M(+96.6%) | $11.02M(+21.9%) |
| Sep 2007 | - | $9.04M(+42.5%) |
| Jun 2007 | - | $6.34M(+34.2%) |
| Mar 2007 | - | $4.73M(-5.1%) |
| Dec 2006 | $16.13M(+18.3%) | $4.98M(+32.2%) |
| Sep 2006 | - | $3.77M(+8.9%) |
| Jun 2006 | - | $3.46M(-5.7%) |
| Mar 2006 | - | $3.67M(+3.0%) |
| Dec 2005 | $13.64M(+50.1%) | $3.56M(-4.7%) |
| Sep 2005 | - | $3.74M(+28.5%) |
| Jun 2005 | - | $2.91M(-9.7%) |
| Mar 2005 | - | $3.22M(+29.4%) |
| Dec 2004 | $9.09M(>+9900.0%) | $2.49M(-23.0%) |
| Sep 2004 | - | $3.23M(+56.9%) |
| Jun 2004 | - | $2.06M(+73.6%) |
| Mar 2004 | - | $1.19M(+2658.4%) |
| Dec 2003 | $0.00(0.0%) | $43.00K(+230.8%) |
| Sep 2003 | - | $13.00K(+7.4%) |
| Jun 2003 | - | $12.10K(+9.0%) |
| Mar 2003 | - | $11.10K(-42.8%) |
| Dec 2002 | $0.00(-100.0%) | $19.40K(-24.5%) |
| Sep 2002 | - | $25.70K(+38.2%) |
| Jun 2002 | - | $18.60K(+35.8%) |
| Mar 2002 | - | $13.70K |
| Dec 2001 | $48.50K | - |
FAQ
- What is Halozyme Therapeutics, Inc. annual total operating expenses?
- What is the all-time high annual operating expenses for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. annual operating expenses year-on-year change?
- What is Halozyme Therapeutics, Inc. quarterly total operating expenses?
- What is the all-time high quarterly operating expenses for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. quarterly operating expenses year-on-year change?
What is Halozyme Therapeutics, Inc. annual total operating expenses?
The current annual operating expenses of HALO is $304.43M
What is the all-time high annual operating expenses for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high annual total operating expenses is $304.43M
What is Halozyme Therapeutics, Inc. annual operating expenses year-on-year change?
Over the past year, HALO annual total operating expenses has changed by +$5.11M (+1.71%)
What is Halozyme Therapeutics, Inc. quarterly total operating expenses?
The current quarterly operating expenses of HALO is $63.34M
What is the all-time high quarterly operating expenses for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high quarterly total operating expenses is $63.34M
What is Halozyme Therapeutics, Inc. quarterly operating expenses year-on-year change?
Over the past year, HALO quarterly total operating expenses has changed by +$3.64M (+6.10%)